Antibody-drug conjugates (ADCs) have emerged as one of the most promising modalities in oncology, offering a way to pair the targeting precision of antibodies with the potency of small-molecule drugs.
Zoltán Gulyás is a senior field applications scientist for the TFF systems and filters at Repligen, providing technical support to customers in Western and Southern Europe. Gulyás has an MSc degree in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results